{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Alcon Inc."},"Symbol":{"label":"Symbol","value":"ALC"},"Address":{"label":"Address","value":"CHEMIN DE BLANDONNET 8,ROYCE BEDWARD, GENEVA, 1214, Switzerland"},"Phone":{"label":"Phone","value":"+41 589112000"},"Industry":{"label":"Industry","value":"Ophthalmic Goods"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan."},"CompanyUrl":{"label":"Company Url","value":"www.alcon.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David J. Endicott","title":"Chief Executive Officer & Director"},{"name":"Edward McGough","title":"Head-Global Manufacturing & Technical Operations"},{"name":"Franck Leveiller","title":"SVP, Head-Global Research & Development"},{"name":"Sue-Jean Lin","title":"SVP, Chief Information & Transformation Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}